Alpha Wave Global’s Alexion Pharmaceuticals ALXN Stock Holding History

Alpha Wave Global’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-384,522	Closed	-$70.6M	–	158
2021 Q2	$70.6M	Sell	384,522 -17,243	-4%	-$2.96M	4.51%	2
2021 Q1	$61.4M	Buy	+401,765	New	+$62.1M	3.82%	4

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Alpha Wave Global's ALXN Position: Q3 2021 in Review

Alpha Wave Global sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 384,522 shares — an estimated $70.6M sold.

Alpha Wave Global first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $70.6M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Alpha Wave Global reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Alpha Wave Global sold 384,522 Alexion Pharmaceuticals shares in Q3 2021, an estimated $70.6M.
Alpha Wave Global first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
Alpha Wave Global's Alexion Pharmaceuticals position peaked at $70.6M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Alpha Wave Global's 13F filing for Q3 2021, filed 12 Nov 2021.